Abbott Laboratories (NYSE:ABT) Price Target Cut to $106.00 by Analysts at Leerink Partners

Abbott Laboratories (NYSE:ABT) had its price objective decreased by Leerink Partners from $119.00 to $106.00 in a report published on Tuesday,MarketScreener reports. Leerink Partners currently has a market perform rating on the healthcare product maker’s stock.

Several other equities analysts have also issued reports on the stock. Stifel Nicolaus decreased their price target on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a report on Friday, April 17th. TD Cowen cut their price objective on shares of Abbott Laboratories from $137.00 to $115.00 and set a “buy” rating on the stock in a research report on Friday, April 17th. Jefferies Financial Group cut their price objective on shares of Abbott Laboratories from $145.00 to $135.00 and set a “buy” rating on the stock in a research report on Friday, April 17th. Raymond James Financial cut their price objective on shares of Abbott Laboratories from $130.00 to $115.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. Finally, Benchmark cut their price target on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating on the stock in a research report on Friday, April 17th. Two investment analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and a consensus price target of $120.35.

Abbott Laboratories Stock Performance

Shares of Abbott Laboratories stock opened at $92.83 on Tuesday. The firm has a 50 day simple moving average of $107.21 and a 200 day simple moving average of $118.00. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.58 and a quick ratio of 1.18. Abbott Laboratories has a fifty-two week low of $92.65 and a fifty-two week high of $139.06. The firm has a market cap of $161.67 billion, a P/E ratio of 26.00, a P/E/G ratio of 1.60 and a beta of 0.79.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.71%. The firm had revenue of $11.16 billion during the quarter, compared to analyst estimates of $10.99 billion. During the same quarter in the previous year, the business earned $1.09 EPS. The business’s quarterly revenue was up 7.8% compared to the same quarter last year. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Sell-side analysts predict that Abbott Laboratories will post 5.53 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be paid a $0.63 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.7%. Abbott Laboratories’s dividend payout ratio is 70.59%.

Insiders Place Their Bets

In other Abbott Laboratories news, VP John A. Jr. Mccoy sold 585 shares of the stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $67,614.30. Following the transaction, the vice president owned 24,628 shares in the company, valued at $2,846,504.24. This represents a 2.32% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Daniel J. Starks bought 10,000 shares of the firm’s stock in a transaction on Wednesday, February 4th. The shares were acquired at an average price of $108.73 per share, for a total transaction of $1,087,300.00. Following the transaction, the director owned 6,738,817 shares in the company, valued at approximately $732,711,572.41. This represents a 0.15% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have sold 3,055 shares of company stock worth $353,097 in the last 90 days. Corporate insiders own 0.46% of the company’s stock.

Hedge Funds Weigh In On Abbott Laboratories

Several institutional investors and hedge funds have recently added to or reduced their stakes in ABT. J. Stern & Co. LLP lifted its stake in Abbott Laboratories by 12,439.6% in the 4th quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock valued at $4,926,279,000 after purchasing an additional 39,005,451 shares during the last quarter. Norges Bank bought a new position in Abbott Laboratories in the 4th quarter valued at approximately $2,938,892,000. Invesco Ltd. raised its stake in shares of Abbott Laboratories by 51.0% during the third quarter. Invesco Ltd. now owns 13,951,907 shares of the healthcare product maker’s stock valued at $1,868,718,000 after acquiring an additional 4,713,135 shares during the last quarter. Assenagon Asset Management S.A. raised its stake in Abbott Laboratories by 303.0% during the first quarter. Assenagon Asset Management S.A. now owns 4,429,571 shares of the healthcare product maker’s stock worth $454,784,000 after buying an additional 3,330,368 shares during the last quarter. Finally, Ninety One UK Ltd bought a new position in Abbott Laboratories during the fourth quarter worth $336,815,000. Institutional investors own 75.18% of the company’s stock.

More Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: UBS kept a “buy” rating on ABT, signaling continued conviction in Abbott’s franchise despite trimming its price target — a vote of confidence from a major bank. UBS Sticks to Their Buy Rating for Abbott Laboratories (ABT)
• Positive Sentiment: Income-minded investors are seeing value: recent coverage highlights a dividend yield near 3% and labels ABT a “dividend king” opportunity for buy-the-dip investors. That supports demand from yield-focused funds. Abbott Laboratories Just Got Interesting: Dividend Yield Near 3% Signals Opportunity
• Positive Sentiment: Progress on Abbott’s CancerGuard multi-cancer early-detection program and new DETECT A outcomes reinforce the company’s long-term diagnostics growth narrative. Positive clinical/award news can support upside over time. Abbott’s CancerGuard Progress Adds New Dimension To Diagnostics Growth Story
• Neutral Sentiment: Options-market activity is drawing attention; spikes in put/call flows can foreshadow moves but aren’t a directional confirmation by themselves. Traders may use this as a signal for volatility, not fundamentals. Is the Options Market Predicting a Spike in Abbott Laboratories Stock?
• Neutral Sentiment: Coverage notes that ABT is trading near its 52-week low while many analysts remain bullish — an outlook that supports buy-side interest if sentiment stabilizes. Wall Street Refuses to Blink: 2 Healthcare Stocks at 52-Week Lows That Analysts Still Love
• Negative Sentiment: Major banks collectively trimmed price targets (multiple firm actions published), creating downward pressure on the stock as headline PT cuts refresh sell-side valuation estimates. This broad re-rating is a primary driver of today’s weakness. Mizuho Cuts Abbott Laboratories Price Target
• Negative Sentiment: UBS and Argus lowered their targets (UBS to $135; Argus to $125) even while keeping buy ratings — a mixed signal that reduces near-term upside expectations vs. prior levels. UBS Adjusts Abbott Laboratories Price Target to $135
• Negative Sentiment: Social and analyst chatter highlights that Q1 results beat estimates but management trimmed full-year guidance (diagnostics headwinds, mild flu season, acquisition costs), which triggered post-earnings selling and still weighs on sentiment. Abbott Laboratories Stock Opinions on Q1 Earnings and Guidance Cut

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.